A Phase 2a, Randomized, Placebo-controlled, Dose-Ranging Study to Evaluate the Safety and Efficacy of PTC518 in Subjects with Huntington’s Disease
This study is looking into a new medication called PTC518 for people living with Huntington's Disease. It's a 'Phase 2a' study, which means researchers are carefully checking its safety and how effective it might be at different doses. Some participants will receive the active medicine, while others will get a placebo (a dummy pill that looks the same but contains no medicine). This helps researchers understand the true effects of PTC518. They will monitor changes in a specific protein in the blood related to Huntington's Disease, as well as checking for any side effects and other health markers. The aim is to find a safe and effective dose.
At a glance
What is this study about?
This clinical trial is exploring a new potential treatment called PTC518 for Huntington's Disease. Huntington's is a complex condition, and scientists are constantly working to find better ways to manage it. This particular study is in an early stage, known as Phase 2a, which focuses on thoroughly checking the safety of the new medicine and trying to work out the best dose to use.
Participants in the study will be split into different groups. Some will receive PTC518 at varying doses, while others will receive a 'placebo'. A placebo is a dummy pill that looks exactly like the real medicine but contains no active ingredients. This is a common and important part of clinical research because it helps researchers understand if the changes they see are truly due to the medicine or if they might happen anyway.
The main things researchers will be looking at are safety — checking for any unwanted side effects and general health changes — and how the medicine affects a specific protein in the blood that is linked to Huntington's Disease. They will also look at how the medicine might impact brain structure and general physical and mental health over time. This information will help them decide if PTC518 is a promising treatment and if it should be tested in larger studies.
Key takeaways
- This study is testing a new medicine (PTC518) for Huntington's Disease.
- It's a safety and dose-finding study (Phase 2a).
- Participants will receive either the active medicine or a dummy pill (placebo).
- Researchers will monitor safety, a specific protein in the blood, and other health markers.
- The study lasts for 12 months and involves regular clinic visits and tests.
- Participation is voluntary, and you can withdraw at any time.
Who may be eligible?
To be considered for this study, you must be an adult, aged 18 years or older, with Huntington's Disease. Both men and women can take part.
There might be other specific health requirements or conditions that would mean you couldn't join the study, even if you meet the age and diagnosis criteria. These detailed rules are in place to make sure the study is as safe as possible for everyone involved and that the results are clear and reliable.
If you're interested, it's really important to discuss this with your doctor or the study team, as they will be able to check all the specific eligibility rules with you.
- Are you 18 years old or older?
- Have you been diagnosed with Huntington's Disease?
- Are you able to attend regular clinic appointments and undergo study tests?
- Are you willing to consider taking either the study medicine or a placebo?
This is a guide only — the research team will confirm whether you can take part.
What does participation involve?
If you decide to take part in this study, you'll be assigned to a group that receives either the study medicine (PTC518) or a placebo (a dummy pill). You won't know which one you're getting, and neither will your study doctor, as this helps make the results fair. You'll take the assigned tablets regularly as instructed. Over the course of the study, you'll have several visits to the clinic.
During these visits, the study team will conduct various assessments. This includes regular checks of your general health, blood tests to look at the protein related to Huntington's and other markers, heart checks (using an ECG), and physical examinations. They will also talk to you about how you're feeling, including any side effects, and assess changes in your symptoms or mood using specific questionnaires.
Some assessments, like brain scans (MRI), will be done a bit less frequently, at specific time points like after 12 months. The study will last for a total of 12 months, with ongoing monitoring and assessment throughout this period.
Potential risks and benefits
Locations (6)
- —Germany
- —Spain
- —Italy
- —Austria
- —Netherlands
- —France
Common questions
What is Huntington's Disease?
Huntington's Disease is a genetic condition that affects the brain, causing uncontrolled movements, mental health issues, and a decline in thinking skills over time.
What does 'Phase 2a' mean?
Phase 2a means this is an early stage of testing where researchers are checking if the medicine is safe, how well it works, and what dose might be best.
What is a placebo?
A placebo is a 'dummy pill' that looks exactly like the real medicine but contains no active ingredients. It helps researchers understand the true effects of the medicine.
Will I know if I'm getting the real medicine?
No, neither you nor your study doctor will know if you're getting the medicine or the placebo. This is to ensure the study results are fair and accurate.
How long will the study last?
The main part of this study will involve taking the study drug and having follow-up appointments over 12 months.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.